Single-centre observational study of anti-adalimumab antibody development in children and young people treated for juvenile idiopathic arthritis and/or non-infectious uveitis.

چکیده

Adalimumab is an effective first-line biologic therapy used to treat children and young people (CYP) with juvenile idiopathic arthritis (JIA) and non-infectious uveitis (NIU). However, the development of neutralising antibodies may compromise adalimumab's efficacy. This study investigated the…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• یووئیت و التهاب داخل چشمی
• چشم پزشکی کودکان